Table 2: Some Criteria of Natriuretic Peptide Guided Trials Including Patients with Heart Failure with Reduced Ejection Fraction.

	Troughton et al.[33]	Beck-da-Silva et al.[34]	STARS-BNP[35]	TIME-CHF[36]	BATTLE-SCARRED[39]	PRIMA[38]	SIGNAL-HF[40]	Berger et al.[37]	UPSTEP[42]	STARBRITE[43]	PROTECT[41]	GUIDE-IT[29]
n	69	41	220	499 (622)	134 (364)	229 (345)	252	177 (278)	279	137	151	894
Blinded	No	No	No	Single	Double	Single	Single	No	Single	Single	No	No
Marker	NT-proBNP	BNP	BNP	NT-proBNP	NT-proBNP	NT-proBNP	NT-proBNP	NT-proBNP	BNP	BNP	NT-proBNP	NT-proBNP
Target (pg/ml)	1,692	Not stated	100	400/800	1,270	Discharge	50% reduction	2,200	150/300	Discharge	1.000	1.000
Control	HF score	HF spec	Usual care	≤ NYHA class II	Two groups	Usual care	HF spec	Two groups	Usual care	HF spec	Usual care	HF spec
Primary endpoint	Death, CV hosp HF	Mean beta-blocker dose achieved	HF death, HF hosp	Death, all-cause hosp	All-cause mortality	Days alive outside hospital	Days alive outside CV hospital	HF hosp, death	Death, HF hosp/worse	Days alive outside hospital	CV events	CV death, HF hosp
Age (mean)	70	65	66	77	76	72	77	71	71	61	63	63
NT-BNP/BNP at baseline (pg/ml)	1,981	~600	350	4,328	2,008	2,940	~2,500	~2,350	851	450	2,118	2,650
Study duration	12 months	90 days	450 days	18 months	3 years	2 years	9 months	18 months	At least 1 year	90 days	1 year	24 months

The total number of patients included if different is shown in parentheses; differences concern patients with heart failure with preserved ejection fraction or undetermined left ventricular ejection fraction, or two control groups. BNP = B-type natriuretic peptide; CV = cardiovascular; HF = heart failure; HF spec = heart failure specialists; hosp = hospitalisation; NT-proBNP = N-terminal pro—B-type natriuretic peptide.